Ligand Pharmaceuticals Inc (LGND)

126.19
0.43 0.34
NASDAQ : Health Care
Prev Close 126.62
Open 125.91
Day Low/High 125.02 / 126.93
52 Wk Low/High 71.63 / 138.94
Volume 172.90K
Avg Volume 232.70K
Exchange NASDAQ
Shares Outstanding 21.05M
Market Cap 2.69B
EPS -0.10
P/E Ratio 10.11
Div & Yield N.A. (N.A)

Latest News

Ligand Reports Second Quarter 2017 Financial Results

Ligand Reports Second Quarter 2017 Financial Results

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three and six months ended June 30, 2017, and provided an operating forecast and program updates.

Ligand To Report Second Quarter 2017 Results On August 7th

Ligand To Report Second Quarter 2017 Results On August 7th

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today plans to report second quarter 2017 financial results on August 7, 2017.

Ligand Enters Into Commercial License And Supply Agreement With Amgen For Rights To Use Captisol In The Formulation Of AMG 330

Ligand Enters Into Commercial License And Supply Agreement With Amgen For Rights To Use Captisol In The Formulation Of AMG 330

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that it has entered into a commercial license and supply agreement with Amgen, granting rights to use Ligand's Captisol technology in the formulation of...

Ligand's Partner Melinta Therapeutics Announces U.S. FDA Approval Of Baxdela™ (Delafloxacin) For Acute Bacterial Skin And Skin Structure Infections (ABSSSI)

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that partner Melinta Therapeutics, a privately held company focused on discovering, developing, and commercializing novel antibiotics to treat serious bacterial...

Ligand Enters Into Worldwide OmniAb® Platform License Agreement With Surface Oncology

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces it has entered into a worldwide license agreement with Cambridge, Massachusetts-based Surface Oncology.

Ligand Announces Aziyo Biologics Acquires Commercial Products From Partner CorMatrix

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces it will receive $10 million from a contractually specified royalty rate buy-down following the sale by CorMatrix Cardiovascular, Inc.

Ligand Enters Into Worldwide OmniAb® Platform License Agreement With XCella Biosciences

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) announces it has entered into a worldwide license agreement with Menlo Park, California-based xCella Biosciences, Inc.

Ligand To Participate In Two Upcoming Investor Conferences

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that company executives are scheduled to participate in the following upcoming investor conferences: 14 th Annual Craig-Hallum Institutional...

Ligand Reports First Quarter 2017 Financial Results

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three months ended March 31, 2017, and provided an operating forecast and program updates.

Ligand To Report First Quarter 2017 Results On May 9th

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today plans to report first quarter 2017 financial results on May 9, 2017.

Ligand Enters Commercial License And Supply Agreements With Marinus Pharmaceuticals For Captisol-Enabled Ganaxolone

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that it has entered into commercial License and Supply Agreements (License Agreement) with Marinus Pharmaceuticals, Inc.

Ligand To Participate In Upcoming Investor Conference

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that company executives are scheduled to participate in the following upcoming investor conference: 29 th Annual ROTH Conference in Laguna...

Ligand Provides Highlights From Today's Analyst Day Event

At an Analyst Day event held today in New York City, Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) reviewed the recent progress of its business, its revenue growth opportunities and its portfolio of partnered assets...

Ligand Expands License With Sermonix To Include Worldwide Rights For Oral Lasofoxifene

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that it has expanded its license with Sermonix Pharmaceuticals to include worldwide rights to develop and commercialize oral lasofoxifene.

6 Stocks with Unusual Volume Activity

6 Stocks with Unusual Volume Activity

When stocks move with unusual volume, it can signal insider buying and selling.

6 Stocks on the Move With Unusual Volume

6 Stocks on the Move With Unusual Volume

Here's a technical look at how to trade a number of stocks rising with unusual volume flow.

Enrollment Completed In Ligand's Phase 2 Trial Of LGD-6972 In Type 2 Diabetes

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) announces the completion of enrollment in the Company's Phase 2 clinical trial with its novel, small-molecule glucagon receptor antagonist LGD-6972 for the treatment of...

Ligand Reports Fourth Quarter And Full Year 2016 Financial Results

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three and 12 months ended December 31, 2016, and provided an operating forecast and program updates.

Dr. Christel Iffland Joins Ligand As Vice President, Antibody Technologies, Expands Team Focused On OmniAb Drug Discovery Platform

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces the appointment of Christel Iffland, Ph.

Reminder: Ligand To Host Analyst Day On February 28th In New York City

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) will host an Analyst Day on Tuesday, February 28, 2017 from 10:00 a.

Ligand To Host Analyst Day On February 28th In New York City

Ligand To Host Analyst Day On February 28th In New York City

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) will host an Analyst Day on Tuesday, February 28, 2017 from 10:00 a.

Ligand To Report Fourth Quarter And Full Year 2016 Results On February 23rd

Ligand To Report Fourth Quarter And Full Year 2016 Results On February 23rd

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today plans to report fourth quarter and full year 2016 financial results on February 23, 2017.

UPCOMING DEADLINE: Levi & Korsinsky, LLP Reminds Shareholders Of Ligand Pharmaceuticals Inc. Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of January 17, 2017

UPCOMING DEADLINE: Levi & Korsinsky, LLP Reminds Shareholders Of Ligand Pharmaceuticals Inc. Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of January 17, 2017

The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Ligand Pharmaceuticals Inc.

LGND SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Reminds Investors Of A Class Action Involving Ligand Pharmaceuticals Inc. And A Lead Plaintiff Deadline Of January 17, 2017

LGND SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Reminds Investors Of A Class Action Involving Ligand Pharmaceuticals Inc. And A Lead Plaintiff Deadline Of January 17, 2017

The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Southern District of California on behalf of investors who purchased Ligand Pharmaceuticals Inc.

DEADLINE ALERT: Brower Piven Reminds Investors Of The January 17, 2017 Deadline In Class Action Lawsuit And Encourages Investors With Losses In Excess Of $100,000 From Investment In Ligand Pharmaceuticals Incorporated To Contact The Firm

DEADLINE ALERT: Brower Piven Reminds Investors Of The January 17, 2017 Deadline In Class Action Lawsuit And Encourages Investors With Losses In Excess Of $100,000 From Investment In Ligand Pharmaceuticals Incorporated To Contact The Firm

The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of California on behalf...

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders Of Ligand Pharmaceuticals Inc. Of Commencement Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of January 17, 2017

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders Of Ligand Pharmaceuticals Inc. Of Commencement Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of January 17, 2017

The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Ligand Pharmaceuticals Inc.

Ligand Enters Commercial License And Supply Agreements For Captisol®-enabled Trametinib

Ligand Enters Commercial License And Supply Agreements For Captisol®-enabled Trametinib

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces it has entered into global license and supply agreements with Novartis for the development and commercialization of a Captisol-enabled oral liquid formulation of...